Progress in Alzheimer’s Disease Builds Renewed Interest in Research
In June of 2021, the FDA approved a new drug, Aduhelm, from the company Biogen for the treatment of mild
October 27, 2021
In June of 2021, the FDA approved a new drug, Aduhelm, from the company Biogen for the treatment of mild
October 18, 2021 Dr. Nicole White, Hampus Hillerstrom, LuMind IDSC and a team of experts, recently published an article in
October 18, 2021 October is Down Syndrome Awareness Month, and to commemorate it, Hampus Hillerstrom, LuMind IDSC’s CEO, wrote an
October 7, 2021 From mom of four to Down syndrome researcher. Research Spotlight sat with Nicole White and discussed some
August 18, 2021 LuMind IDSC has joined the National Down Syndrome Society (NDSS) and The National Task Group on Intellectual
LuMind IDSC has joined the National Down Syndrome Society (NDSS) and The National Task Group on Intellectual Disabilities and Dementia
People with Down syndrome live longer and more independently now than ever before. Supported by advances in medical care, community
“It is unknown to what degree aducanumab (Aduhelm) may help people with Down syndrome, as they were not included among
June 29, 2021 This blogpost from a former FDA insider on the power of the patient helps us understand how
Today marks an important milestone in Alzheimer’s disease research with the approval by the FDA of Aduhelm (aducanumab) from the